Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low - Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares reached a new 52-week low during trading on Friday . The company traded as low as $25.74 and last traded at $25.80, with a volume of 324671 shares changing hands. The stock had previously closed at $27.04.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday. They issued a "buy" rating and a $50.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Price Performance

The firm's 50 day moving average price is $32.03 and its 200-day moving average price is $36.50. The stock has a market cap of $1.45 billion, a P/E ratio of -34.13 and a beta of -2.78.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock valued at $341,015,000 after buying an additional 221,851 shares during the period. FMR LLC lifted its holdings in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company's stock valued at $268,977,000 after acquiring an additional 383,635 shares during the period. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Driehaus Capital Management LLC grew its stake in shares of Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company's stock valued at $101,204,000 after purchasing an additional 86,833 shares during the period. Finally, Federated Hermes Inc. grew its stake in shares of Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company's stock valued at $94,531,000 after purchasing an additional 150,000 shares during the period. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.